术前联合检测血清肿瘤标志物诊断消化系统肿瘤的临床价值

The value of preoperative combined detection of several serum tumor markers in patients with digestive system neoplasm

目的探讨几种血清肿瘤标志物术前检测在消化系统肿瘤诊断中的应用价值。方法回顾性分析90例已确诊的消化系统恶性肿瘤的术前血清的及37例对照者的肿瘤标志物AFP、CEA、CA50、CA19-9和CA242的水平,应用放射免疫分析技术检测这些肿瘤标志物的含量。结果胃癌组的阳性率分别为AFP(12.00%)、CEA(68.00%)、CA50(28.00%)、CA19-9(48.00%)和CA242(12.00%);肝癌组的阳性率分别为AFP(81.25%)、CEA(12.50%)、CA50(62.50%)、CA19-9(50.00%)和CA242(6.25%);胰腺癌组的阳性率分别为AFP(55.56%)、CEA(41.18%)、CA50(27.78%)、CA19-9(72.22%)和CA242(88.89%);结肠癌组的阳性率分别为AFP(22.58%)、CEA(35.48%)、CA50(83.87%)、CA19-9(90.32%)和CA242(29.03%);对照组的阳性率分别为AFP(8.11%)、CEA(2.70%)、CA50(5.41%)、CA19-9(0.00%)和CA242(0.00%);联合检测的阳性率分别为76.00%、68.75%、94.44%和93.55%。结论多种肿瘤标志物联合检测可以提高消化系统恶性肿瘤诊断的阳性率,在肿瘤的术前诊断中有较高的临床应用价值。

Objective To explore the clinic value of preoperative combined detection of several serum tumor markers in patients with digestive system neoplasm.Methods From January 2004 to December 2005,90 cases with malignant tumor of digestive system and 37 cases as control person were analyzed retrospectively. These cases were detected in the tumor marker levels by the radioimmunoassay. Results The positive rate of tumor markers in group of stomach cancer were AFP（12.00%）, CEA（68.00%）, CA50（28.00%）, CA19-9（48.00%） and CA242（12.00%）respectively. Liver cancer group was AFP（81.25%）, CEA （12.50%）, CA50（62. 50%）, CA19-9（50.00%） and CA242（6.25%） respectively. Pancreatic cancer group was AFP （55.56%）,CEA（41.18%）, CA50（27.78%）, CA19-9（72.22%） and CA242（88.89%） respectively Colon cancer group was AFP（22.58%）, CEA（35.48%）, CA50（83.87%）, CA19-9（90.32%） and CA242 （29.03%）respectively. The normal cases were AFP（8.11%）, CEA（2.70%）, CA50（5. 41%）, CA19-9 （0.00%） and CA242 （0.00%） respectively. The positive rate of conbined detection were 76.00%, 68.75%, 94.44% and 93.55% respectively. Conclusion It could improve the positive diagnosis rate to use several tumor markers combined detection, especially in the preoperative tumor patients.